US FDA Regulations for Novel and Innovative Products
Questions? Request more information from our specialists
CONTACT USReady to sell your novel device in the United States? In a system based on predicate devices and substantial equivalence, marketing an innovative or novel device comes with some unique challenges. What do you do when your innovative device has no predicate?
As the range of novel and innovative medical devices continues to grow, the challenge for both industry and the US FDA is to determine the best way to get these new devices to health care providers and patients as soon as possible, while ensuring safety and effectiveness. In this whitepaper, we discuss your options for bringing your novel device to the US market.
What you will learn in this 7-page white paper:
- What are the common regulatory pathways in the US?
- What does novel mean?
- What to do if your device is truly novel?
- What is the de novo process?
- What is humanitarian device exemption (HDE)?
- What is the expedited access pathway (EAP)?
Get answers to all of these questions and more in this white paper.
About the Author
Audrey Swearingen, RAC (US): Audrey Swearingen is Director of Regulatory Affairs at Emergo's Austin, Texas headquarters. With over 20 years of experience in regulatory affairs, Audrey's areas of expertise include US FDA medical device registration, as well as European and Canadian device registration.
Related
-
How to Prepare for an FDA Inspection
Are you ready for a random audit by the FDA? If you are lucky, you might only have a few weeks or even days to get ready for a visit from the FDA.
read more -
Determining Substantial Equivalence for FDA Device Clearance
Substantial equivalence is the key to getting your Class II medical device cleared for sale by the US Food and Drug Administration. The bulk of the
read more